Miyazaki et al. suggested that AIM is involved in the progression of metabolic syndrome, including obesity and IR, in both an advancing and inhibitory fashion[9], but the impact of AIM on the pathogenesis of HCV-related chronic liver disease has not been investigated. This evidence concerns the gene CD5L and Obesity.